BRPI0908906A2 - compostos heterocíclicos e usos dos mesmos - Google Patents

compostos heterocíclicos e usos dos mesmos

Info

Publication number: BRPI0908906A2
Authority: BR; Brazil
Prior art keywords: heterocyclic compounds; heterocyclic; compounds
Prior art date: 2008-03-21

Application number

BRPI0908906A

Other languages

English (en)

Inventor

Smith Aaron

M Shafer Cynthia

Poon Daniel

Jin Jeff

Sendzik Martin

Mckenna Maureen

A Renhowe Paul

Zhang Qiong

D Machajewski Timothy

Anotnio-Mccrea William

Xu Yongjin

Huang Zilin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-21

Filing date

2009-03-19

Publication date

2019-09-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40734805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908906(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-19 Application filed by Novartis Ag filed Critical Novartis Ag

2019-09-24 Publication of BRPI0908906A2 publication Critical patent/BRPI0908906A2/pt

Links

150000002391 heterocyclic compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0908906A 2008-03-21 2009-03-19 compostos heterocíclicos e usos dos mesmos BRPI0908906A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3872308P	2008-03-21	2008-03-21
US20845809P	2009-02-24	2009-02-24
PCT/EP2009/053245 WO2009115572A2 (en)	2008-03-21	2009-03-19	Novel heterocyclic compounds and uses therof

Publications (1)

Publication Number	Publication Date
BRPI0908906A2 true BRPI0908906A2 (pt)	2019-09-24

Family

ID=40734805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908906A BRPI0908906A2 (pt)	2008-03-21	2009-03-19	compostos heterocíclicos e usos dos mesmos

Country Status (26)

Country	Link
US (1)	US8129394B2 (pt)
EP (1)	EP2274300A2 (pt)
JP (2)	JP5384611B2 (pt)
KR (2)	KR20130040258A (pt)
CN (1)	CN102015686B (pt)
AR (1)	AR071283A1 (pt)
AU (1)	AU2009227013B2 (pt)
BR (1)	BRPI0908906A2 (pt)
CA (1)	CA2718936A1 (pt)
CL (1)	CL2009000687A1 (pt)
CO (1)	CO6311078A2 (pt)
CR (1)	CR11681A (pt)
DO (1)	DOP2010000280A (pt)
EA (1)	EA201001456A1 (pt)
EC (1)	ECSP10010559A (pt)
IL (1)	IL208063A0 (pt)
MA (1)	MA32232B1 (pt)
MX (1)	MX2010010317A (pt)
NI (1)	NI201000156A (pt)
PE (1)	PE20091656A1 (pt)
SM (1)	SMAP201000115A (pt)
SV (1)	SV2010003673A (pt)
TW (1)	TW201000457A (pt)
UY (1)	UY31724A (pt)
WO (1)	WO2009115572A2 (pt)
ZA (1)	ZA201006505B (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE028588T2 (hu)	2005-12-13	2016-12-28	Incyte Holdings Corp	Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JP5483880B2 (ja) *	2006-10-23	2014-05-07	武田薬品工業株式会社	イミノピリジン誘導体およびその用途
EP2740731B1 (en)	2007-06-13	2016-03-23	Incyte Holdings Corporation	Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8865732B2 (en) *	2008-03-21	2014-10-21	Novartis Ag	Heterocyclic compounds and uses thereof
US20110039892A1 (en) *	2008-04-23	2011-02-17	Takeda Pharmaceutical Company Limited	Iminopyridine derivative and use thereof
US8481569B2 (en) *	2008-04-23	2013-07-09	Takeda Pharmaceutical Company Limited	Iminopyridine derivatives and use thereof
KR20100130235A (ko) *	2008-04-23	2010-12-10	다케다 야쿠힌 고교 가부시키가이샤	이미노피리딘 유도체 및 이의 용도
NZ596479A (en)	2009-05-22	2014-01-31	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BRPI1012108B8 (pt)	2009-05-22	2021-05-25	Incyte Corp	composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
US8242260B2 (en)	2009-08-28	2012-08-14	Novartis Ag	Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
CA2789696C (en)	2010-02-25	2017-11-07	Dana-Farber Cancer Institute, Inc.	Braf mutations conferring resistance to braf inhibitors
CA2792508C (en)	2010-03-10	2018-01-16	Incyte Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA202091303A3 (ru)	2010-05-21	2021-05-31	Инсайт Холдингс Корпорейшн	Композиция ингибитора jak для местного применения
AU2011274914B2 (en) *	2010-07-09	2013-07-18	Mitsubishi Gas Chemical Company, Inc.	Photochromic material
CA2804845A1 (en)	2010-07-12	2012-01-19	Stuart Ince	Substituted imidazo[1,2-a]pyrimidines and -pyridines
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es)	2010-11-19	2015-05-25	Incyte Corporation	Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
WO2012135631A1 (en) *	2011-03-30	2012-10-04	Arrien Pharmaeuticals Llc	Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
US8691807B2 (en)	2011-06-20	2014-04-08	Incyte Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
WO2013059634A1 (en)	2011-10-20	2013-04-25	The Regents Of The University Of California	Use of cdk9 inhibitors to reduce cartilage degradation
JP6150813B2 (ja)	2011-11-11	2017-06-21	ノバルティスアーゲー	増殖性疾患の治療方法
CA2856406C (en)	2011-11-23	2020-06-23	Novartis Ag	Pharmaceutical formulations
US9408885B2 (en)	2011-12-01	2016-08-09	Vib Vzw	Combinations of therapeutic agents for treating melanoma
CN103159735B (zh) *	2011-12-10	2015-12-09	通化济达医药有限公司	取代的咪唑激酶抑制剂
TW201331194A (zh) *	2011-12-23	2013-08-01	Millennium Pharm Inc	雜芳基化合物及其用途
CN104470515B (zh)	2012-05-03	2016-12-07	圣路易斯药学院	用于增加神经营养肽的组合物和方法
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2014047330A1 (en) *	2012-09-19	2014-03-27	Jean-Michel Vernier	Novel raf kinase inhibitors
KR102242077B1 (ko)	2012-11-15	2021-04-20	인사이트 홀딩스 코포레이션	룩솔리티니브의 서방성 제형
EP3489239B1 (en)	2013-03-06	2021-09-15	Incyte Holdings Corporation	Processes and intermediates for making a jak inhibitor
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
MX376856B (es)	2013-08-07	2025-03-07	Incyte Holdings Corp	Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
UY36294A (es)	2014-09-12	2016-04-29	Novartis Ag	Compuestos y composiciones como inhibidores de quinasa
US10300073B2 (en)	2014-10-14	2019-05-28	The Regents Of The University Of California	Use of CDK9 and BRD4 inhibitors to inhibit inflammation
US10870651B2 (en)	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
KR101665231B1 (ko) *	2015-01-30	2016-10-13	순천향대학교 산학협력단	티오페닐 그룹을 갖는 티아졸계 화합물 및 이를 유효성분으로 포함하는 항진균제
JP6581213B2 (ja) *	2015-02-04	2019-09-25	メドパクトインコーポレイテッド	慢性骨髄性白血病の予防用または治療用の薬学的組成物、及びそれを利用した方法
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
GB201614934D0 (en) *	2016-09-02	2016-10-19	Glaxosmithkline Intellectual Property (No 2) Ltd	Chemical compounds
GB201614940D0 (en) *	2016-09-02	2016-10-19	Glaxosmithkline Intellectual Property (No 2) Ltd	Chemical compounds
CN109715163B (zh)	2016-09-19	2022-11-22	诺华股份有限公司	包含raf抑制剂和erk抑制剂的治疗组合
JP7258748B2 (ja) *	2016-11-22	2023-04-17	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
KR102515694B1 (ko)	2017-01-10	2023-03-29	바이엘 악티엔게젤샤프트	해충 방제제로서의 헤테로사이클 유도체
TW201837026A (zh)	2017-01-10	2018-10-16	德商拜耳廠股份有限公司	作為除害劑之雜環衍生物（二）
EP3579872A1 (en)	2017-02-10	2019-12-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
ES3053505T3 (en) *	2017-03-23	2026-01-22	Clavius Pharmaceuticals Llc	Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment
WO2018203219A1 (en)	2017-05-02	2018-11-08	Novartis Ag	Combination therapy
JP7038994B2 (ja) *	2017-10-16	2022-03-22	国立大学法人金沢大学	炭素繊維強化プラスチックの製造方法、炭素繊維強化プラスチック及びセルロース系樹脂
TW201924683A (zh)	2017-12-08	2019-07-01	美商英塞特公司	用於治療骨髓增生性贅瘤的低劑量組合療法
CA3086765A1 (en)	2017-12-28	2019-07-04	Tract Pharmaceuticals, Inc.	Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
MD3746429T2 (ro)	2018-01-30	2022-08-31	Incyte Corp	Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
KR20260080448A (ko)	2018-03-30	2026-06-02	인사이트 코포레이션	Jak 억제제를 사용하는 화농성 한선염의 치료
EP3810132A4 (en)	2018-06-25	2022-06-22	Dana-Farber Cancer Institute, Inc.	TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
WO2020011141A1 (zh) *	2018-07-12	2020-01-16	深圳市塔吉瑞生物医药有限公司	一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2020041562A1 (en)	2018-08-22	2020-02-27	Clavius Pharmaceuticals, Llc	Substituted imidazoles for the inhibition of tgf-beta and methods of treatment
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN113164477A (zh)	2018-12-14	2021-07-23	达纳-法伯癌症研究所股份有限公司	C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en)	2018-12-28	2022-09-07	Dana-Farber Cancer Institute, Inc.	CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
WO2020150091A1 (en)	2019-01-15	2020-07-23	Merck Sharp & Dohme Corp.	Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
WO2020168197A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh)	2019-03-05	2021-01-01	美商英塞特公司	作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
CN111356687B (zh) *	2019-03-27	2021-03-30	广州必贝特医药技术有限公司	含嘧啶的三取代咪唑类化合物及其应用
US11919904B2 (en)	2019-03-29	2024-03-05	Incyte Corporation	Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	Tricyclic amine compounds as cdk2 inhibitors
EP4563150A3 (en)	2019-05-13	2025-07-23	Novartis AG	New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2021030537A1 (en)	2019-08-14	2021-02-18	Incyte Corporation	Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es)	2019-10-11	2022-10-10	Incyte Corp	Aminas bicíclicas como inhibidoras de la cdk2
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
BR112022026904A2 (pt)	2020-07-02	2023-01-24	Bayer Ag	Derivados de heterocicleno como agentes de controle de pragas
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
US11905272B1 (en)	2023-09-12	2024-02-20	King Faisal University	3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound
US11932619B1 (en)	2023-09-13	2024-03-19	King Faisal University	3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound
US11993579B1 (en)	2023-09-13	2024-05-28	King Faisal University	3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1h-imidazol-2-yl)pyridin-4-ol as an anti-microbial compound

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3707475A (en) *	1970-11-16	1972-12-26	Pfizer	Antiinflammatory imidazoles
JPS5613715A (en) *	1979-07-13	1981-02-10	Nec Corp	Manufacture of coil
DE3029376A1 (de) *	1980-07-31	1982-03-18	Nepera Chemical Co. Inc., Harriman, N.Y.	Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
US5243517A (en) *	1988-08-03	1993-09-07	Westinghouse Electric Corp.	Method and apparatus for physiological evaluation of short films and entertainment materials
JP2722586B2 (ja) *	1989-01-13	1998-03-04	大正製薬株式会社	インドリルイミダゾール誘導体
JP2808460B2 (ja)	1989-11-16	1998-10-08	大正製薬株式会社	イミダゾール誘導体
US6850252B1 (en) *	1999-10-05	2005-02-01	Steven M. Hoffberg	Intelligent electronic appliance system and method
US5436830A (en) *	1993-02-01	1995-07-25	Zaltman; Gerald	Metaphor elicitation method and apparatus
US5676148A (en) *	1995-03-31	1997-10-14	Siemens Medical Systems Inc.	Method and system for doppler ultrasound audio dealiasing
US5717100A (en) *	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL123950A (en) *	1995-10-06	2001-04-30	Merck & Co Inc	Substituted imidazoles having anti-cancer and cytokine inhibitory activity and pharmaceutical compositions containing them
US5676138A (en) *	1996-03-15	1997-10-14	Zawilinski; Kenneth Michael	Emotional response analyzer system with multimedia display
WO1998008845A1 (en) *	1996-08-27	1998-03-05	Novartis Ag	Herbicidal s-substituted 1,2,4,6-thiatriazines
US6315569B1 (en) *	1998-02-24	2001-11-13	Gerald Zaltman	Metaphor elicitation technique with physiological function monitoring
US6099319A (en) *	1998-02-24	2000-08-08	Zaltman; Gerald	Neuroimaging as a marketing tool
US6358201B1 (en) *	1999-03-02	2002-03-19	Doc L. Childre	Method and apparatus for facilitating physiological coherence and autonomic balance
JP2000302680A (ja) *	1999-04-23	2000-10-31	Takeda Chem Ind Ltd	脳保護剤
CA2395564A1 (en) *	1999-11-22	2001-05-31	Smithkline Beecham Plc	Novel compounds
MXPA02007134A (es) *	2000-01-18	2003-03-27	Vertex Pharma	Inhibidores de girasa y usos de los mismos.
AR029803A1 (es) *	2000-02-21	2003-07-16	Smithkline Beecham Plc	Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0005357D0 (en) *	2000-03-06	2000-04-26	Smithkline Beecham Plc	Compounds
GB0007405D0 (en) *	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
DE60108745T2 (de) *	2000-05-19	2005-07-07	The Nutrasweet Co., Chicago	Herstellung von N-[N-(3,3-Dimethylbutyl)-L-α-aspartyl]-L-phenylalanin-1-methylester mittels Oxazolidinonderivate
ES2289004T3 (es) *	2000-11-20	2008-02-01	Smithkline Beecham Corporation	Nuevos compuestos.
AU2002241966A1 (en) *	2001-01-26	2002-08-28	Chugai Seiyaku Kabushiki Kaisha	Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
AR039241A1 (es) *	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
CN1681805A (zh) *	2002-09-18	2005-10-12	辉瑞产品公司	作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
AU2004289539C1 (en)	2003-11-14	2012-06-07	Lorus Therapeutics Inc.	Aryl imidazoles and their use as anti-cancer agents
NZ549003A (en) *	2004-03-05	2009-07-31	Taisho Pharmaceutical Co Ltd	Thiazole derivative as an ALK5 inhibitor
KR100749566B1 (ko) *	2004-04-21	2007-08-16	이화여자대학교 산학협력단	Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20060106020A1 (en) *	2004-04-28	2006-05-18	Rodgers James D	Tetracyclic inhibitors of Janus kinases
PE20060315A1 (es) *	2004-05-24	2006-05-15	Irm Llc	Compuestos de tiazol como moduladores de ppar
US7453002B2 (en) *	2004-06-15	2008-11-18	Bristol-Myers Squibb Company	Five-membered heterocycles useful as serine protease inhibitors
JP2007246520A (ja)	2006-02-15	2007-09-27	Takeda Yuichiro	Ｒａｇｅ阻害剤

2009
- 2009-03-19 WO PCT/EP2009/053245 patent/WO2009115572A2/en not_active Ceased
- 2009-03-19 EA EA201001456A patent/EA201001456A1/ru unknown
- 2009-03-19 CA CA2718936A patent/CA2718936A1/en not_active Abandoned
- 2009-03-19 MX MX2010010317A patent/MX2010010317A/es active IP Right Grant
- 2009-03-19 JP JP2011500226A patent/JP5384611B2/ja not_active Expired - Fee Related
- 2009-03-19 EP EP09722890A patent/EP2274300A2/en not_active Withdrawn
- 2009-03-19 BR BRPI0908906A patent/BRPI0908906A2/pt not_active IP Right Cessation
- 2009-03-19 AU AU2009227013A patent/AU2009227013B2/en not_active Ceased
- 2009-03-19 CN CN200980114791.8A patent/CN102015686B/zh not_active Expired - Fee Related
- 2009-03-19 KR KR1020137005251A patent/KR20130040258A/ko not_active Abandoned
- 2009-03-19 US US12/383,035 patent/US8129394B2/en not_active Expired - Fee Related
- 2009-03-19 KR KR1020107023491A patent/KR101408517B1/ko not_active Expired - Fee Related
- 2009-03-20 UY UY0001031724A patent/UY31724A/es not_active Application Discontinuation
- 2009-03-20 AR ARP090101010A patent/AR071283A1/es unknown
- 2009-03-20 PE PE2009000430A patent/PE20091656A1/es not_active Application Discontinuation
- 2009-03-20 TW TW098109220A patent/TW201000457A/zh unknown
- 2009-03-20 CL CL2009000687A patent/CL2009000687A1/es unknown
2010
- 2010-09-07 IL IL208063A patent/IL208063A0/en unknown
- 2010-09-10 ZA ZA2010/06505A patent/ZA201006505B/en unknown
- 2010-09-20 NI NI201000156A patent/NI201000156A/es unknown
- 2010-09-20 DO DO2010000280A patent/DOP2010000280A/es unknown
- 2010-09-21 SV SV2010003673A patent/SV2010003673A/es not_active Application Discontinuation
- 2010-09-21 CR CR11681A patent/CR11681A/es not_active Application Discontinuation
- 2010-10-15 MA MA33252A patent/MA32232B1/fr unknown
- 2010-10-20 SM SM201000115T patent/SMAP201000115A/it unknown
- 2010-10-21 CO CO10130723A patent/CO6311078A2/es not_active Application Discontinuation
- 2010-10-21 EC EC2010010559A patent/ECSP10010559A/es unknown
2013
- 2013-10-02 JP JP2013207483A patent/JP2014040452A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
SV2010003673A (es)	2011-07-05
CA2718936A1 (en)	2009-09-24
US20100003246A1 (en)	2010-01-07
CN102015686B (zh)	2014-07-02
ECSP10010559A (es)	2010-11-30
JP5384611B2 (ja)	2014-01-08
CN102015686A (zh)	2011-04-13
KR101408517B1 (ko)	2014-06-17
MX2010010317A (es)	2010-10-04
EP2274300A2 (en)	2011-01-19
IL208063A0 (en)	2010-12-30
UY31724A (es)	2009-11-10
CL2009000687A1 (es)	2010-03-26
CR11681A (es)	2010-10-29
AU2009227013B2 (en)	2013-01-10
JP2014040452A (ja)	2014-03-06
KR20100136516A (ko)	2010-12-28
JP2011515371A (ja)	2011-05-19
TW201000457A (en)	2010-01-01
AR071283A1 (es)	2010-06-09
EA201001456A1 (ru)	2011-06-30
WO2009115572A2 (en)	2009-09-24
SMAP201000115A (it)	2011-01-19
CO6311078A2 (es)	2011-08-22
AU2009227013A1 (en)	2009-09-24
NI201000156A (es)	2011-03-15
MA32232B1 (fr)	2011-04-01
WO2009115572A3 (en)	2009-12-03
DOP2010000280A (es)	2012-09-15
KR20130040258A (ko)	2013-04-23
PE20091656A1 (es)	2009-11-20
US8129394B2 (en)	2012-03-06
ZA201006505B (en)	2011-05-25

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BR112012003709A2 (pt)	2016-04-05	compostos heterocíclicos e usos dos mesmos
BRPI0920927A2 (pt)	2019-09-24	derivados de azaquinolinona e usos dos mesmos
BRPI0914682A2 (pt)	2015-10-20	compostos de heteroarila e usos dos mesmos
BRPI1014997A2 (pt)	2019-09-24	compostos heteroarila e usos dos mesmos
NL300891I2 (nl)	2017-11-21	Lotilaner en zouten daarvan
BRPI0909469A2 (pt)	2015-12-29	compostos de oximetileno de arila e usos dos mesmos
BRPI0912198A2 (pt)	2019-09-24	anticorpos anti-fn14 e usos dos mesmos
BR112013013790A2 (pt)	2016-09-13	compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
HRP20180718T1 (hr)	2018-07-13	Oligopeptidni spojevi i njihova upotreba
BRPI0819909A2 (pt)	2017-12-19	anticorpos antimesotelina e usos dos mesmos
PT3037529T (pt)	2019-05-31	Polipéptidos ph20 estendidos solúveis e suas utilizações
BRPI1013943A2 (pt)	2015-09-01	Composto cetais e usos dos mesmos.
BRPI0912480A2 (pt)	2015-12-29	compostos de monoalquiltina de alta pureza e usos dos mesmos
BRPI1011970A2 (pt)	2015-09-22	compostos pirazolil-acrilonitrila e usos dos mesmos.
BRPI1015315A2 (pt)	2018-02-20	composto heterocíclico fundido e uso dos mesmos
BRPI1009455A2 (pt)	2016-03-01	anticorpos anti-c40 e usos dos mesmos
BRPI0907231A2 (pt)	2019-09-24	pirrolpirimidinas e pirrolpiridinas
BRPI0918045A2 (pt)	2015-12-01	compostos de carboxamida heterocíclicos
BRPI1011404A2 (pt)	2016-03-15	mutantes e usos dos mesmos
DK2594567T3 (da)	2020-09-28	Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
DOP2010000044A (es)	2010-03-31	Derivado de oxopirazina y herbicida
BRPI0906980A2 (pt)	2015-07-21	Composição de derivados e maleatados
BRPI1008752A2 (pt)	2016-03-08	compostos alquilamido e usos dos mesmos
BRPI1010024A2 (pt)	2019-09-24	derivados de aminopirrolidinona e uso dos mesmos
BR112012006501A2 (pt)	2016-08-16	polipeptídios e usos dos mesmos